No Interferon in Phase 3 Trials of Hep C Drug PSI-7977 | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Vertex Launching 3-Month Study of Incivek

Back to News Homepage
Next

HCV Previous Non-Responders Have Twice the Viral Clearance with TMC435

No Interferon in Phase 3 Trials of Hep C Drug PSI-7977

The Editors at Hepatitis Central
November 4, 2011

Print this page

Based on previous encouraging results, Pharmasett’s PSI-7977 will begin Phase 3 testing in three distinct Hepatitis C trials – all without interferon.

November 1, 2011

Hep C Inhibitor PSI-7977 Goes Interferon-Free in Phase III Studies

Princeton, New Jersey-based Pharmasset is putting its lead experimental hepatitis C nucleotide inhibitor to the test in three late-stage clinical trials exploring the drug’s safety and efficacy as a component of a regimen that only needs to be taken for three months and that doesn’t include pegylated interferon, according to a November 1 announcement by the company. If all goes well in the studies, the company will petition the U.S. Food and Drug Administration (FDA) to begin the process of reviewing PSI-7977 for approval sometime in the second half of 2013.

Continue reading this entire article:
http://www.aidsmeds.com/articles/pharmasset_psi7977_trials_1667_21386.shtml

No Comments - be the first!
Share
Share
Previous

Vertex Launching 3-Month Study of Incivek

Back to News Homepage
Next

HCV Previous Non-Responders Have Twice the Viral Clearance with TMC435

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.